reMYND

reMYND is a company that specializes in protein misfolding diseases. It enables clients to assess in-vivo characteristics, pharmacokinetics, pharmacodynamics, and the effects of their treatments against Alzheimer's disease. The company also develops a phenotypic screening platform that helps to discover disease-modifying small molecule treatments and their mechanism of action to counteract the toxicity induced by misfolded proteins.